Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
NCT07204314Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Oct 2025
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Vortioxetine with Placebo (2 arms). Primary endpoint: Children Depression Rating Scale Revised version Total Score at 14 weeks. Started Oct 2025; status: recruiting.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07204314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204314.